Skip to content
H

Huda M. Alkreathy

Publications (3)

In vivo and In vitro Antifungal Activity of 2,3-Dimethylquinoxline

Abdelbagi Alfadil, Hamoud A. Alsamhan, Ahmed S. Ali, Huda M. Alkreathy, Mohammad W. Alrabia & Hani Y. Abdullah · Journal of Pharmaceutical Research International · 2021

Aims: To explore the antifungal activity of 2,3-dimethylquinoxaline. Study Design: A preclinical study of a compound against 10 fungal species. Backgrounds: Severe fungal infections cause significant clinical problem and need more effort to search for new antifungals. Methodology...

Open access Research Article 10.9734/jpri/2021/v33i31A31684

Major Adverse Effects Associated with Tacrolimus (Fk506) Based Regimen among Saudi Kidney Transplant Patients

Ahmed S. Ali, Marzog S. Al-Nasser, Mai A. Abdul Sattar, Huda M. Alkreathy, Mohammed N. Al-Amma, Rayan A. Alsulaimani & Ezz H. Abdulfattah · Journal of Pharmaceutical Research International · 2018

Tacrolimus (Fk506)- based immunosuppressant regimen has become the cornerstone in managing kidney transplant patients (KTP) , where it has been used typically used on chronic basis. However, various adverse effects on multiple organ systems are expected and their incidence is dep...

Open access Research Article 10.9734/JPRI/2018/41611

Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile

Ahmed S. Ali, Mahran S. Abdel-Rahman, Riyadh S. Almalikil, Abir S. Mohamed, Khalid A. Alfaifi, Abdelbabgi El. Fadil, Nagla A. El-Shitany & Huda M. Alkreathy · Journal of Pharmaceutical Research International · 2020

After the global pandemic of the new coronavirus, its rapid spread and many victims, it is necessary to find an effective vaccine or drugs to overcome it. Most specialists consider that repositioning some medications is the best, fastest and most reliable option for treating pati...

Open access Research Article 10.9734/jpri/2020/v32i830468